Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

Introduction: SDHB pathogenic variants predispose to aggressive and metastatic paragangliomas (mPGLs). International consensus recommends temozolomide treatment (low-grade evidence). Capecitabine and temozolomide (CAPTEM) has shown advantage over temozolomide in the treatment of neuroendocrine tumours (NETs). Evidence for its use in mPGLs remains scarce.

Conference:

Presenting Author: G. Martins R

Authors: Silva L, Martins R, Couto J, Garcia R, Martins Fernandes A,

Keywords: mPGL, SDHB, captem,

#4384 The efficacy of combination of temozolomide and capecitabine for neuroendocrine tumours: A real-world comparison of outcomes in Alberta, Canada – Patients treated from 2011-2021

Introduction: The combination of capecitabine and temozolomide (CAPTEM) showed PFS benefits in pancreatic neuroendocrine tumours (PNETs).

Conference:

Presenting Author:

Authors: Aleksi A, Malek H, Husi P, Halperin H, White-Gloria C,

Keywords: captem, neuroendocrine tumour, endocrine tumour, progression-free survival, overall survival,

#4006 Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

Introduction: Thymic neuroendocrine neoplasms (T-NENs) are rare mediastinal malignancies that lack established treatment guidelines. While the Capecitabine and Temozolomide (CapTem) regimen has demonstrated significant efficacy in patients with pancreatic NENs, its applicability and effectiveness in treating T-NENs remain underexplored.

Conference:

Presenting Author: Liu M

Authors: Liu M, Yan X, Lin X, Chen L, Wang Y,

Keywords: Capecitabine plus Temozolomide, Thymic Neuroendocrine Neoplasm, CapTem, T-NEN,

#3864 Efficacy and safety of capecitabine and temozolomide (CAPTEM) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) – A systematic review and metanalysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous tumors, with multiple therapeutic options for advanced stages. The combination of capecitabine and temozolomide (CAPTEM) is increasingly used for advanced GEP-NEN, but evidence on results is sparse.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Massironi S, Gallo C, Bina N, Stornello C,

Keywords: chemotherapy, pfs, progression-free survival, adverse events,

#3572 Capecitabine and temozolomide in advanced neuroendocrine neoplasms – A single center experience

Introduction: Neuroendocrine neoplasms (NENs) are heterogeneous malignancies, with a great variability in clinical behaviour and prognosis. Capecitabine and temozolomide combination (CAPTEM) has shown positive results in these patients, with a good safety profile.

Conference:

Presenting Author:

Authors: Monteiro J, Caetano A, Pires M, Costa C, Elvas A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor, treatment, capecitabine, temozolomide, capecitabine and temozolomide, CAPTEM,